Innate Immunity · 2012 · 135 citations · 29 references
Life SciencesImmunologyOncologyCancer ImmunologyInnate ImmunityTumor ImmunologyColorectal CancerCytokines In Tumor ImmunityImmune Cell InfiltrationNatural Killer Cell BiologyNatural Killer Cell RegulationTumor-infiltrating LymphocytesAlterationAntitumor Cytokine ResponsesAntitumor Immune ActivationCo-culture ModelsImmune Evasion By TumorsImmune Response InductionInnate Antitumor ImmunityPeripheral Blood Natural Killer Cells
Despite NK cells being originally identified because of their ability to kill tumor cells in vitro, only limited information is available on NK cells infiltration of malignant tumors, especially in humans. NK cells infiltrating human colorectal carcinomas (CRCs) were analyzed to identify their potential protective role in an antitumor immune response. The expression and function of relevant molecules were analyzed from different sources, comparing tumor-associated NK cells (TANKs) with autologous peripheral blood NK cells (PB-NKs) from CRC patients-the latter in comparison with PB-NKs from normal donors. TANKs displayed a profound alteration of their phenotype with a drastic reduction of NK cell receptor expression. Co-culture experiments showed that CRC cells produce modulation in NK phenotype and functionality. Moreover, PB-NKs from CRC patients also exhibited an altered phenotype and profound defects in the ability to activate degranulation and IFN-γ production. For the first time, TANK and PB-NK cells from CRC patients have been characterized. It is shown that they are not capable of producing relevant cytokines and degranulate. Taken together, our results suggest that NK cells from CRC patients present alterations of phenotype and function therefore supporting the progression of cancer.
29
Ahmedin Jemal, Rebecca L. Siegel, Elizabeth M. Ward et al. · CA A Cancer Journal for Clinicians · 2006 · 5.3K citations · Full text
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre et al. · New England Journal of Medicine · 2009 · 3.9K citations · Full text
Medicine, Oncology, Pharmacology +17
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Klas Kärre, Hans Ljunggren, Gerald E. Piontek et al. · Nature · 1986 · 2.1K citations
Life Sciences, Immunology, Oncology +12
Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset
Megan A. Cooper, Todd A. Fehniger, Sarah C. Turner et al. · Blood · 2001 · 1.4K citations
Adaptive immunity maintains occult cancer in an equilibrium state
Catherine Koebel, William Vermi, Jeremy B. Swann et al. · Nature · 2007 · 1.4K citations
Life Sciences, Immunology, Oncology +16